Catalogue Number: 18275-IBL
|Manufacturer:||IBL - (Immuno-Biologicals Laboratories Co Ltd)|
|Type:||Polyclonal Primary Antibody - Unconjugated|
|Shipping Condition:||Blue Ice|
|Unit(s):||100 ug, 10 ug|
|Immunogen:||Synthetic peptide of the C terminal part of rat GRO/CINC-2α|
Description: GRO (Growth Related Oncogene) belonging to IL-8 family is polypeptide which has three isoforms α, β and γ, and it inhibits proliferation of endothelial cells. GRO/CINC-1 (cytokine-induced neutrophil chemo attractant 1) was originally purified from media conditioned by IL-1β stimulated rat kidney epithelioid cells (NRK-52E.) Amino acid sequence that encodes rat CINC-1 was identified in 1989 by Watanabe's group at Toyama Medical and Pharmaceutical University. CINC-1 is a member of the alpha (CXC) subfamily of chemokines. Three additional rat CXC chemokines (CINC-2α, CINC-2β, CINC-3/MIP-2) have been identified. The protein sequence of CINC-1 is 63 - 67% identical to that of CINC-2α, CINC-2β and CINC-3/MIP-2. In addition, each of GROα, GROβ and GROγ is sharing 68%, 71% and 69% identity with CINC-1. This has been suggested that CINCs are the rat counterparts of human GROs. GROα/MGSA has a high homology with IL-8 in amino acid sequences. It has been reported that it also has a similar configuration in 3D structural analysis and the almost same level of leukocyte chemotaxis with IL-8. Also its production from activated monocyte, fibroblast, epithelial and endothelial cells has been reported. It has been reported that GROβ inhibits angiogenesis in case of administration of GRO in vivo. Mouse KC (Keratinocyto-derived Cytokine) is a counterpart of human GRO protein and it has been reported that KC is produced in such as activated monocyte and fibroblast. Mouse MIP (Macrophage Inflammatory Protein) is polypeptide which has leukocyte chemotaxis and it originally was discovered as a small protein (molecular weight about 8 kDa) induced by the lipo-polysaccharide stimulation in the macrophage cell line. Two kinds, MIP-1 and MIP-2 are identified by the research afterwards.